Pfizer announced on Wednesday it has launched a late-stage clinical trial to test a flu vaccine built using the same mRNA technology behind its Covid-19 shot, one of the most advanced studies for this kind of vaccine as firms push to expand beyond Covid and build upon the successes of the pandemic.
Pfizer is trialling an mRNA flu shot. Europa Press via Getty Images
Key Facts
Pfizer said it had dosed the first participants in the Phase 3 clinical trial designed to test an mRNA-based influenza vaccine designed using the same technology used in its widely-used Covid-19 vaccine, which it developed with German firm BioNTech.
Subscribe to Forbes Australia for full access to this and all articles today
We use cookies to help us to deliver our services and provide personalised experiences. By using this website you agree to use our cookies.
Cookie Policy
